Novoste appoints Getz for Pacific Rim:
This article was originally published in Clinica
Australian company Getz has agreed to oversee the commercialisation and distribution of Novoste's Beta-Cath system in Australia and New Zealand following a three- year agreement. The product is designed to inhibit restenosis by delivering radiation therapy to the artery immediately after an angioplasty procedure (see Clinica, No 866, p 15). According to Norcross, Georgia-based Novoste, the Beta-Cath system is the first vascular brachytherapy device to become commercially available in Australia. It is already on sale in Europe and undergoing clinical trials in the US.
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.